Zobrazeno 1 - 10
of 35
pro vyhledávání: ''
Autor:
Sara Small, Shuo Ma
Publikováno v:
Current Hematologic Malignancy Reports. 16:325-335
The treatment options for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have expanded significantly in the last few years, including the use of new classes of oral small molecular inhibitors targeting the B cell receptor signaling
Autor:
Kah Poh Loh, Saurabh Dahiya, Anita J. Kumar, Maya Abdallah, Nina Rosa Neuendorff, Heidi D. Klepin
Publikováno v:
Curr Hematol Malig Rep
PURPOSE OF REVIEW: The treatment landscape for older patients with acute myeloid leukemia (AML) is evolving. Many treatments have comparable efficacy making their impact on quality of life (QoL) an important differentiating factor. In this review, we
Publikováno v:
Current Hematologic Malignancy Reports
Hematologic malignancies are most likely to present in the seventh and eighth decades of life. Continued population growth will lead to increasing numbers of older adults with hematologic malignancies. Oncology care for older adults is complex and mu
Publikováno v:
Current Hematologic Malignancy Reports. 12:309-316
Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as we
Publikováno v:
Current Hematologic Malignancy Reports. 12:290-299
Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the
Autor:
Yasir Khan, Elizabeth Brem
Publikováno v:
Current hematologic malignancy reports. 14(4)
Diffuse large B cell lymphoma (DLBCL) is a curable and common malignancy in elderly population. Elderly patients, especially those 80 and older, have poor outcomes compared with those
Publikováno v:
Current hematologic malignancy reports. 14(2)
Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising
Publikováno v:
Current hematologic malignancy reports. 13(2)
Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic appr
Publikováno v:
Current Hematologic Malignancy Reports. 8:261-269
In recent years, the treatment of multiple myeloma has undergone significant changes. The availability of novel agents bortezomib, thalidomide and lenalidomide considerably improved the outcome of patients. The advantages related to the use of novel
Publikováno v:
Current Hematologic Malignancy Reports. 8:173-183
Post-transplant lymphoproliferative diseases (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that complicate solid organ or hematopoietic transplantation. Risk factors have been iden